Clinical Pathway for Evaluation and Treatment of
Child with Acute COVID-19 Infection
Child with Acute COVID-19 Infection
(+) SARS-CoV-2 PCR or antigen test and clinical symptomsDetermine Severity of Illness
Mild/Moderate
- Fever, fatigue, myalgia
- Nasal congestion, sore throat
- Cough
- Tachypnea without supplemental O2 requirement or pneumonia
Severe
Hypoxemia requiring supplemental O2 requirement via nasal cannula
Critical
- Hypoxemia or respiratory distress requiring high-flow nasal cannula, non-invasive positive pressure ventilation, mechanical ventilation, or ECMO
- Septic shock
Consider labs/imaging
Assess presence of high-risk conditionsNo High-Risk Condition
High-Risk Condition
Admit to inpatient or PICU special treatment room
Treatment recommendations by illness severity
Treatment recommendations by illness severity
Child ≥ 12 yrs old
and
≥ 40 kg
and
≥ 40 kg
Child < 12 yrs old
or
< 40 kg
or
< 40 kg
Discharge
Supportive care- Discharge
- Supportive care
- Consider outpatient Paxlovid
- Discharge
- Supportive care
- Consider remdesivir with subspecialty service
Evidence
- IDSA COVID-19 Treatment Guidelines
- Guideline for Prevention and Management of COVID-19 in Children and Adolescents: a Consensus Statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
- Dexamethasone in Hospitalized Patients with COVID-19
- Remdesivir for the Treatment of COVID-19 – Final Report
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19
- Tocilizumab in Patients Admitted to the Hospital with COVID-19 (RECOVERY): a Randomized, Controlled, Open-label Platform Trial
- Baricitinib Plus Remdesivir for Hospitalized Adults with COVID-19
- Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with COVID-19 (COV-BARRIER): a Randomized, Double-blind, Parallel Group, Placebo-controlled Phase 3 Trial
- Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients
- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with COVID-19
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19